Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Acute Decompensated Heart Failure

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This clinical trial aims to compare the efficacy and safety of acetazolamide versus metolazone as adjunctive treatments to standard therapy in patients with acute decompensated heart failure (ADHF). ADHF is a life-threatening condition, and current treatments often involve loop diuretics to alleviate volume overload. This study will assess the added benefit of acetazolamide and metolazone in improving decongestion, reducing hospital stays, and preventing complications such as renal dysfunction or electrolyte imbalances. Participants will be randomized to receive either acetazolamide or metolazone in addition to standard diuretic therapy. The trial will evaluate primary outcomes including successful decongestion, in-hospital mortality, and length of hospital stay, with secondary outcomes focusing on renal function, electrolyte disturbances, and overall safety. The study is conducted at Bahawal Victoria Hospital, Bahawalpur, and aims to provide valuable insights into the management of ADHF, especially in the Pakistani population.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Aged 18 years or older.

• Diagnosed with Acute Decompensated Heart Failure (ADHF), with either preserved or reduced ejection fraction (EF).

• At least one clinical sign of volume overload, such as:

• Pleural effusion (confirmed by chest X-ray or ultrasound).

• Oedema or ascites (verified by abdominal ultrasonography).

• Plasma NT-proBNP level \> 1000 pg/mL or BNP level \> 250 ng/mL at screening.

• Receiving at least 40 mg of furosemide as oral maintenance therapy for at least one month prior to the study initiation.

Locations
Other Locations
Pakistan
Quaid e Azam Medical College , bahawalpur
RECRUITING
Chak Eighty-seven -twelve Left
Contact Information
Primary
Matiullah Azmoon
matiullahazmoon@gmail.com
03221639240
Time Frame
Start Date: 2025-10-11
Estimated Completion Date: 2026-10-30
Participants
Target number of participants: 320
Treatments
Experimental: Acetazolamide + Standard Therapy
Participants in this group will receive acetazolamide (500 mg/day) as an adjunct to standard heart failure therapy, which includes intravenous loop diuretics (Furosemide 80 mg/day). This group aims to assess the efficacy and safety of acetazolamide in improving decongestion in patients with acute decompensated heart failure.
Active_comparator: Metolazone Group
Participants in this group will receive metolazone (5 mg/day) as an adjunct to standard heart failure therapy, including intravenous loop diuretics (Furosemide 80 mg/day). This group serves as a comparison to the acetazolamide group, evaluating the efficacy and safety of metolazone in improving decongestion in patients with acute decompensated heart failure.
Related Therapeutic Areas
Sponsors
Leads: University of Health Sciences Lahore

This content was sourced from clinicaltrials.gov